Corvus Pharmaceuticals, Inc.
COMBINATION THERAPY FOR CANCER TREATMENT
Last updated:
Abstract:
Provided herein are, inter alia, methods for treating cancer in subjects expressing elevated levels of adenosine A2A receptors, and optionally further expressing elevated levels of CD73 and/or PD-L1, by administering adenosine pathway inhibitors and PD-1 pathway inhibitors.
Status:
Application
Type:
Utility
Filling date:
6 Nov 2018
Issue date:
20 Aug 2020